StemRIM Inc. (JP:4599)
:4599
Top Page
StemRIM Inc.
(4599)
Select Model
Select Model
Rating:45Neutral
Price Target:
¥273.00
▲(7.06% Upside)
Action:ReiteratedDate:03/24/26
The score is driven primarily by weak financial performance—revenue disappearance, large losses, and ongoing cash burn—partly cushioned by an extremely low-debt balance sheet. Technical indicators are neutral to slightly weak with price below key moving averages, and valuation is constrained by loss-making status and no dividend support.
Positive Factors
Extremely low leverage
Near-zero debt materially reduces financial risk and preserves strategic flexibility. Over a multi-month horizon this lower leverage supports funding R&D or bridging financing without immediate insolvency risk, making the firm less vulnerable to interest shocks or credit-market tightening.
Negative Factors
Revenue disappearance
A complete drop to zero revenue indicates loss of recurring cash-generating activity and heavy reliance on irregular, non-recurring deals. Over months this erodes predictability, undermines planning for R&D and operations, and heightens dependency on financing or partner payments.
Read all positive and negative factors
Positive Factors
Negative Factors
Extremely low leverage
Near-zero debt materially reduces financial risk and preserves strategic flexibility. Over a multi-month horizon this lower leverage supports funding R&D or bridging financing without immediate insolvency risk, making the firm less vulnerable to interest shocks or credit-market tightening.
Read all positive factors
StemRIM Inc. (4599) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥18.99B
Dividend YieldN/A
Average Volume (3M)122.86K
Price to Earnings (P/E)―
Beta (1Y)1.08
Revenue GrowthN/A
EPS Growth11.34%
CountryJP
Employees44
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.42
Shares Outstanding62,681,200
10 Day Avg. Volume118,910
30 Day Avg. Volume122,863
Financial Highlights & Ratios
PEG Ratio1.85
Price to Book (P/B)2.69
Price to Sales (P/S)0.00
P/FCF Ratio-13.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-30.8
Revenue Forecast (FY)N/A
StemRIM Inc. Business Overview & Revenue Model
Company Description
StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. It develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis...
StemRIM Inc. Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
72
Positive
Cash Flow
30
Negative
| Breakdown | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 | Jul 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 2.35B | 22.98M | 1.40B |
| Gross Profit | -49.50M | -44.35M | 2.30B | 0.00 | 0.00 |
| EBITDA | -1.92B | -2.03B | 190.18M | -1.93B | -550.13M |
| Net Income | -1.93B | -2.02B | 168.35M | -1.95B | -582.45M |
Balance Sheet | |||||
| Total Assets | 7.52B | 9.09B | 10.72B | 9.61B | 10.93B |
| Cash, Cash Equivalents and Short-Term Investments | 6.99B | 8.41B | 10.22B | 8.88B | 10.17B |
| Total Debt | 0.00 | 0.00 | 531.00K | 3.67M | 6.73M |
| Total Liabilities | 210.27M | 194.06M | 348.51M | 207.74M | 231.10M |
| Stockholders Equity | 7.31B | 8.89B | 10.37B | 9.40B | 10.70B |
Cash Flow | |||||
| Free Cash Flow | -1.46B | -1.88B | 1.14B | -1.40B | -608.70M |
| Operating Cash Flow | -1.41B | -1.88B | 1.14B | -1.40B | -519.65M |
| Investing Cash Flow | -42.50M | -4.78M | -344.00K | -330.00K | -92.72M |
| Financing Cash Flow | 41.25M | 78.97M | 202.60M | 112.86M | 109.32M |
StemRIM Inc. Technical Analysis
Positive
255.00
Price Trends
296.10
Positive
283.26
Positive
295.02
Positive
Market Momentum
1.78
Negative
52.78
Neutral
63.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4599, the sentiment is Positive. The current price of 255 is below the 20-day moving average (MA) of 298.30, below the 50-day MA of 296.10, and below the 200-day MA of 295.02, indicating a bullish trend. The MACD of 1.78 indicates Negative momentum. The RSI at 52.78 is Neutral, neither overbought nor oversold. The STOCH value of 63.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4599.
StemRIM Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | ¥7.84B | 59.41 | ― | 1.24% | -14.78% | -95.53% | |
56 Neutral | ¥16.36B | 120.78 | ― | ― | 1.24% | -33.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥24.41B | -34.16 | ― | ― | -5.65% | -469.19% | |
50 Neutral | ¥50.09B | -13.30 | ― | ― | -82.33% | 47.73% | |
49 Neutral | ¥11.20B | -8.14 | ― | ― | -42.49% | -2.37% | |
45 Neutral | ¥18.99B | -11.30 | ― | ― | ― | 11.34% |
* Healthcare Sector Average
JP:4599
StemRIM Inc.
303.00
32.00
11.81%
JP:4593
Healios KK
371.00
149.00
67.12%
JP:4880
CellSource Co., Ltd.
395.00
-213.89
-35.13%
JP:4978
ReproCELL Inc.
172.00
43.00
33.33%
JP:7774
Japan Tissue Engineering Co., Ltd.
601.00
196.00
48.40%
JP:7776
CellSeed Inc.
288.00
-179.00
-38.33%
StemRIM Inc. Corporate Events
StemRIM Unveils Midterm FY2026 Results and R&D Progress in Regenerative Medicine
Mar 13, 2026
StemRIM Inc. released presentation materials outlining its financial results for the six months ended January 31, 2026 and provided an overview of management indicators, financial summaries, and key business highlights. The update also detailed pr...
StemRIM narrows interim loss as it ramps R&D on regenerative drug pipeline
Mar 11, 2026
StemRIM reported no operating revenue and a net loss of ¥928 million for the six months to Jan. 31, 2026, narrowing slightly from the previous year’s ¥1,048 million loss as basic loss per share improved to ¥14.91. Total assets...
StemRIM Wins Key Patent on Gene Therapy SR-GT1 for Dystrophic Epidermolysis Bullosa
Mar 2, 2026
StemRIM Inc. announced that a Japanese patent has been granted for a stem cell gene therapy technology, SR-GT1, designed to provide a curative treatment for dystrophic epidermolysis bullosa, a severe hereditary skin disorder caused by defects in t...
StemRIM Wins Canadian Patent for Redasemtide Use in Cartilage Disorders
Feb 17, 2026
StemRIM Inc. has secured a forthcoming Canadian patent covering the use of its peptide drug candidate Redasemtide, an HMGB1 fragment peptide, as a therapeutic agent for a broad spectrum of cartilage disorders including osteoarthritis, meniscal dam...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.